Outcome and complications in postcardiotomy cardiogenic shock treated with extracorporeal life support – a systematic review and meta-analysis by Romana Maria Kienlein, Ralf Felix Trauzeddel, Nilufar Akbari, Leonello Avalli, Fausto Biancari, Carlotta Sorini Dini, Sabina Guenther, Christian Hagl, Matthias Heringlake, Jochen Kruppa, Timo Mäkikallio, Raphael Martins, Marc Pineton de Chambrun, Ardawan Julian Rastan, Antonio Rubino, Floris van den Brink, Michael Nordine, Sascha Treskatsch

Get full text

Trial protocol of an open-label pilot study of oral naltrexone–bupropion combination pharmacotherapy for the treatment of methamphetamine use disorder (the NABU trial) by Jonathan Brett, Paul S Haber, Nicholas Lintzeris, Didier Jutras-Aswad, Nadine Ezard, Brendan Clifford, Krista J Siefried, Adrian John Dunlop, Liam Acheson, Carl Moller, Michael Christmass, Kirsten Morley, Steven Shoptaw, Madhukar H Trivedi

“…All participants will receive treatment as usual, such as psychosocial therapy. Primary outcomes are safety (measured by treatment-emergent adverse events (AEs)/adverse reactions) and feasibility (measured by the time taken to recruit, the proportion of ineligible participants, retention in the study and study medication adherence). …”
Get full text

HEROIC: a 5-year observational cohort study aimed at identifying novel factors that drive diabetic kidney disease: rationale and study protocol by Neil Ashman, Ben Caplin, David Wheeler, Tahseen Ahmad Chowdhury, Kieran Mccafferty, Sinead Knight, Paul Hockings, Stanley L Fan, Johannes Hulthe, Robert Kleta, Vasilios Papastefanou, Hemal Mehta, Alan Salama, Sinela Hadzovic, Lisa Jarl, Robert Unwin, Benjamin Challis, Anna K Sundgren, Muhammad Magdi Yaqoob

“…The study is 90% powered to detect an association between key histological and imaging parameters and a composite of death, renal replacement therapy or a 30% decline in estimated GFR.Ethics and dissemination Ethical approval has been obtained from the Bloomsbury Research Ethics Committee (REC 18-LO-1921). …”
Get full text

Cardiovascular Disease and Other Competing Causes of Death in Older Kidney Cancer Patients by Yinglan Liang, Liangjia Zeng, Ruoyun Zhou, Manting Feng, Linglong Liu, Kexin Chen, Jinqi Huang, Haowen Liang, Baixin He, Binghua Zhang, Yican Ying, Yuerong Chen, Tianwang Guan, Min Yi

Get full text

Pharmacological action of Angelica sinensis polysaccharides: a review by Chunzhen Ren, Chunzhen Ren, Chunzhen Ren, Yali Luo, Xiaojuan Li, Like Ma, Chunling Wang, Chunling Wang, Chunling Wang, Xiaodong Zhi, Xiaodong Zhi, Xinke Zhao, Xinke Zhao, Xinke Zhao, Yingdong Li, Yingdong Li, Yingdong Li

“…This review summarizes the research progress on the extraction, chemical structure, pharmacological effects, and mechanisms of ASP and its derivatives by reviewing relevant national and international literature and provides comprehensive information and a reliable basis for the exploration of new treatment strategies involving botanical drugs for disease therapy. Literature information was obtained from scientific ethnobotany and ethnomedicine databases (up to September 2024), mainly from the PubMed, Web of Science, and CNKI databases. …”
Get full text

Unveiling the Mechanisms of a Remission in Major Depressive Disorder (MDD)-like Syndrome: The Role of Hippocampal Palmitoyltransferase Expression and Stress Susceptibility by Careen A. Schroeter, Anna Gorlova, Michael Sicker, Aleksei Umriukhin, Alisa Burova, Boris Shulgin, Sergey Morozov, Joao P. Costa-Nunes, Tatyana Strekalova

“…Our data suggest that <i>Dhhc8</i> and <i>Dhhc14</i> are likely to be implicated in the mechanisms of depression at the remission stage, serving as targets for preventive therapy.…”
Get full text

Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults by Florence Ader, Jean-François Timsit, Yazdan Yazdanpanah, François-Xavier Lescure, Laetitia Moinot, Christelle Delmas, Hélène Espérou, Laurent Abel, Benjamin Leveau, Vinca Icard, Toni Alfaiate, Linda Wittkop, Charles Burdet, France Mentré, Marion Schneider, Nathan Peiffer-Smadja, Julien Poissy, Lila Bouadma, Bruno Lina, Florence Morfin-Sherpa, Maude Bouscambert, Alexandre Gaymard, Gilles Peytavin, Jeremie Guedj, Claire Andrejak, Cedric Laouenan, Drifa Belhadi, Axelle Dupont, Basma Basli, Anissa Chair, Samira Laribi, Julie Level, Marie-Capucine Tellier, Aline Dechanet, Dominique Costagliola, Sandrine Couffin-Cadiergues, Juliette Saillard, Claire Fougerou, Carole Cagnot, Soizic Le Mestre, Delphine Lebrasseur-Longuet, Ventzislava Petrov-Sanchez, Alpha Diallo, NoéMie Mercier, Sarah Tubiana, Benjamin Hamze, Ambre Gelley, Marion Noret, Eric D’Ortenzio, Oriane Puechal, Caroline Semaille

“…The objective of the trial is to evaluate the clinical efficacy and safety of different investigational re-purposed therapeutics relative to Standard of Care (SoC) in patients hospitalised with COVID-19.Methods and analysis DisCoVeRy is a phase III, open-label, adaptive, controlled, multicentre clinical trial in which hospitalised patients with COVID-19 in need of oxygen therapy are randomised between five arms: (1) a control group managed with SoC and four therapeutic arms with re-purposed antiviral agents: (2) remdesivir + SoC, (3) lopinavir/ritonavir + SoC, (4) lopinavir/ritonavir associated with interferon (IFN)-β−1a + SoC and (5) hydroxychloroquine + SoC. …”
Get full text

Potential pharmacological effect of Quercetin Phytosome™ in the management of hyperuricemia: results from real-life clinical studies by Francesco Di Pierro, Francesco Di Pierro, Francesco Di Pierro, Fazle Rabbani, Meherullah Tareen, Roohi Nigar, Amjad Khan, Nicola Zerbinati, Maria L. Tanda, Massimiliano Cazzaniga, Alexander Bertuccioli, Alexander Bertuccioli, Paolo Falasca, Gabriele Damiani, Nicola Villanova

“…With high tolerability, these findings highlight Quercetin Phytosome™'s potential as a safe adjunctive therapy for hyperuricemia management, meriting further investigation in larger, randomized trials to confirm its efficacy and safety.Clinical Trial Registrationclinicaltrials.gov, identifier NCT06652035.…”
Get full text

Cohort profile: the Viral load Cohort North-East Lesotho (VICONEL) from 2016 to 2023 – cohort description, test volumes, predictors of viraemia and the road ahead by Tracy Glass, Frédérique Chammartin, Jochen Ehmer, Thomas Klimkait, Alain Amstutz, Josephine Muhairwe, Irene Ayakaka, Blaise Lukau, Jennifer Anne Brown, Lipontso Motaboli, Malebanye Lerotholi, Maurus Kohler, Kathrin Haenggi, Moliehi Mokete, Makobefo Gladys Chakela, Mpho Kao, Mathebe Kopo, Moleboheng Mokebe, Lorena Urda, Bienvenu Lengo Nsakala, Anna Klicpera, Nadine Tschumi, Niklaus Daniel Labhardt

“…At the time of the last viral load test, median age was 42 years (IQR: 33–53); 18 511 (63%) were adult women, 10 029 (34%) adult men and 835 (3%) children &lt;15 years (age/sex missing for 5) and median time taking antiretroviral therapy (ART) was 6.4 years (IQR 3.2–9.9). Overall, the proportion of cohort participants with viral suppression to &lt;1000 copies/mL has continually exceeded 90% and has been above 95% since 2020; however, this proportion has consistently been lower among children. …”
Get full text

Exploring the Role of Radiosurgery for Atypical Meningiomas: Addressing Suboptimal Local Control in High-Risk Patients by Sanjeev Sreenivasan, MD, MCh, Salem Najjar, BA, Daniel Ma, MD, Sabrina L. Begley, BS, Yen-Ruh Wuu, MD, Zaker Rana, MD, Emile Gogineni, DO, Michael Schulder, MD, Anuj Goenka, MD

“…Conclusions: Our institutional data on atypical patients with meningioma treated with radiosurgery compare favorably to existing literature using fractionated radiation therapy. SRS offers a promising strategy to improve LC in this patient population, and the occurrence of marginal failure plays a role in creating clinical target volume margins.…”
Get full text

Optogenetic control of mitochondrial aggregation and function by Luhao Zhang, Luhao Zhang, Luhao Zhang, Xuechun Liu, Min Zhu, Min Zhu, Yuanfa Yao, Zhichao Liu, Xianming Zhang, Xin Deng, Yi Wang, Liting Duan, Xiaogang Guo, Junfen Fu, Yingke Xu, Yingke Xu, Yingke Xu

“…This study establishes a novel optogenetic-based strategy to regulate mitochondrial dynamics in cells, which may provide a potential therapy for treating mitochondrial-related diseases.…”
Get full text

Impact of carbapenem-resistant infections on mortality in mechanically ventilated acute respiratory distress syndrome patients: A comparison with hypoxemia severity – An observatio... by Thejesh Srinivas, Shwethapriya R, Gagana Hanumaiah, Pratibha Todur, Souvik Chaudhuri, Ganesh Paramasivam, Prithvishree Ravindra, Vinutha R. Bhat, Sagar Shanmukhappa Maddani, Shobha U. Kamath, Danavath Nagendra, Vishwas P, Likith Hanumaiah, Pratik Paran Medhi, Prabha Prakash

Get full text

RETRACTED ARTICLE: Extracorporeal membrane oxygenation support for SARS-CoV-2: a multi-centered, prospective, observational study in critically ill 92 patients in Saudi Arabia by Saad Alhumaid, Abbas Al Mutair, Header A. Alghazal, Ali J. Alhaddad, Hassan Al-Helal, Sadiq A. Al Salman, Jalal Alali, Sana Almahmoud, Zulfa M. Alhejy, Ahmad A. Albagshi, Javed Muhammad, Amjad Khan, Tarek Sulaiman, Maha Al-Mozaini, Kuldeep Dhama, Jaffar A. Al-Tawfiq, Ali A. Rabaan

“…Objectives To describe the effect of ECMO rescue therapy on patient-important outcomes in patients with severe SARS-CoV-2. …”
Get full text

Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end‐stage of renal disease by Seonhwa Lee, Jaewon Oh, Hyoeun Kim, Jaehyung Ha, Kyeong‐hyeon Chun, Chan Joo Lee, Sungha Park, Sang‐Hak Lee, Seok‐Min Kang

“…SV down‐titration group had adverse events including symptomatic hypotension (systolic blood pressure <100 mmHg) (n = 4) and dizziness (n = 1), but they did not discontinue SV therapy. Conclusions We found that SV could safely reduce the hsTnT and sST2 levels and improve LVEF in HFrEF patients with ESRD. …”
Get full text

Structure of Patients with Hepatocellular Cancer (Data Analysis from Two Specialised Centres) by M. V. Mayevskaya, M. S. Novruzbekov, I. M. Borovkov, D. G. Trofimova, M. S. Zharkova, V. D. Lunkov, K. N. Lutsyk, O. D. Olisov

“…The highest five-year survival rate (100 %) was found in the group of patients who received antiviral therapy (AVT) before and after liver transplantation.Conclusions. …”
Get full text

Integrated bioinformatics analysis to explore potential therapeutic targets and drugs for small cell carcinoma of the esophagus by Maofei Zhu, Maofei Zhu, Yueming Chu, Yueming Chu, Qiang Yuan, Qiang Yuan, Junfeng Li, Silin Chen, Lin Li, Lin Li, Lin Li

Get full text

Establishment and validation a relapse prediction model for bipolar disorder by Xiaoqian Zhang, Xiaoqian Zhang, Xiaoqian Zhang, Xiaoqian Zhang, Minghao Wu, Daojin Wang, Long Wang, Long Wang, Long Wang, Wen Xie, Wen Xie, Wen Xie

“…According to the results of univariate and multivariate logistic regression analyses, the number of prior episodes (odds ratio [OR]: 1.38, 95% confidence interval [CI]: 1.179–1.615), Social Disability Screening Schedule (SDSS) score (OR: 1.303, 95% CI: 1.027-1.652), Pittsburgh Sleep Quality Index (PSQI) (OR: 1.476, 95% CI: 1.29-1.689), Number of visits(OR: 0.768, 95% CI: 0.684-0.863), suicidal behaviors (OR: 5.54, 95% CI: 1.818-16.881) and the electroconvulsive therapy (ECT) (OR: 0.382, 95% CI: 0.156-0.94) were independent risk factors for relapse in patients with BD. …”
Get full text

Epidemiology of community-acquired pneumonia among hospitalised children in Indonesia: a multicentre, prospective study by Rina Triasih, Yan Mardian, Dewi Lokida, Helmia Farida, Herman Kosasih, Adhella Menur Naysilla, Arif Budiman, Chakrawati Hayuningsih, Moh Syarofil Anam, Dwi Wastoro, Mujahidah Mujahidah, Setya Dipayana, Amalia Setyati, Abu Tholib Aman, Nurhayati Lukman, Muhammad Karyana, Ahnika Kline, Aaron Neal, Chuen-Yen Lau, Clifford Lane

“…Children were excluded if they had been hospitalised for &gt;24 hours; had malignancy or history of malignancy; a history of long-term (&gt;2 months) steroid therapy, or conditions that might interfere with compliance with study procedures.Main outcome(s) measure(s) Causative bacterial, viral or mixed pathogen(s) for pneumonia were determined using microbiological, molecular and serological tests from routinely collected specimens (blood, sputum and nasopharyngeal swabs). …”
Get full text

Risk of adverse cardiovascular events based on common genetic variants in 8-year follow-up of the LIPIDOGEN2015 population using the polygenic risk score (PRS): study design and me... by Maciej Banach, Martyna Fronczek, Tadeusz Osadnik, Agnieszka Gach, Dominik Strapagiel, Marcin Słomka, Mateusz Lejawa, Anna Goc, Ewa Boniewska-Bernacka, Anna Pańczyszyn, Gregory Y.H. Lip, Dimitri P. Mikhailidis, Peter P. Toth, Peter E. Penson, Jacek Jóźwiak

“…Using the developed PRS scale and biochemical analyses, we will assess the effectiveness of lipid-lowering therapy with statins in patients with high and low genetic risk of sudden CVD events (secondary endpoints). …”
Get full text

Projeto de extensão universitária ‘SaúHDe renal’: Efeitos na qualidade de vida e na aptidão física by Jordana Letícia Buratti, Thaís Severo Dutra, Moane Marchesan Krug, Clara Suemi da Costa Rosa, Paulo Ricardo Moreira, Robelius De-Bortoli, Rodrigo de Rosso Krug

“…For that, patients at the Renal Unit Therapy from the south of Brazil were divided into a control group (CG), composed of patients with a frequency lower or equal to 75% in TF, and an experimental group (EG), composed of patients with a frequency greater than 75% in TF. …”
Get full text